Rutherford Crossing Dialysis in Winchester, Virginia - Dialysis Center

Rutherford Crossing Dialysis is a medicare approved dialysis facility center in Winchester, Virginia and it has 13 dialysis stations. It is located in Frederick county at 141 Market Street, Winchester, VA, 22603. You can reach out to the office of Rutherford Crossing Dialysis at (540) 665-5169. This dialysis clinic is managed and/or owned by Davita. Rutherford Crossing Dialysis has the following ownership type - Profit. It was first certified by medicare in January, 2017. The medicare id for this facility is 492704 and it accepts patients under medicare ESRD program.

Dialysis Center Profile

NameRutherford Crossing Dialysis
Location141 Market Street, Winchester, Virginia
No. of Dialysis Stations 13
Medicare ID492704
Managed ByDavita
Ownership TypeProfit
Late Shifts No

Contact Information


141 Market Street, Winchester, Virginia, 22603
(540) 665-5169
Not Available

News Archive

Congress returns to face health program costs, budget issues

News outlets report that lawmakers are returning to work after a two-week recess, during which they faced emotional challenges from constituents regarding the deficit and the nation's entitlement programs.

Labopharm's public offering underwriters exercise over-allotment option to purchase additional 1.7M units

Labopharm Inc. today announced that the underwriters for the recently announced public offering of newly issued units have exercised in full their over-allotment option to purchase an additional 1,764,706 units. The 1,764,706 additional units are being sold at the public offering price of US$1.70 per unit and will bring the total number of units issued under the public offering to 13,529,412 units.

ONGLYZA-metformin combination: FDA accepts NDA for review

Bristol-Myers Squibb Company and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for an investigational fixed dose combination of ONGLYZA™ (saxagliptin), a dipeptidyl peptidase-4 (DPP4) inhibitor, and metformin HCl extended-release tablets as a once-daily treatment for type 2 diabetes mellitus in adults.

Smell produced by young bed bugs repels other bed bugs

Bed bugs are an increasingly common pest that necessitates extensive decontamination of homes. However, researchers from Lund and Sundsvall in Sweden have now discovered that young bed bugs produce a smell that repels other bed bugs. It is hoped that these findings could contribute to more effective control of the blood-sucking insects.

Countries most susceptible to toxic pollution are also at highest risk from the impacts of global climate change

Mapping the global distribution of toxic pollution alongside the effects of climate change shows the same countries are most vulnerable to both.

Read more Medical News

› Verified 7 days ago


Map and Direction



NPI Associated with this Dialysis Facility:

Dialysis Facilities may have multiple NPI numbers. We have found possible NPI number/s associated with Rutherford Crossing Dialysis from NPPES records by matching pattern on the basis of name, address, phone number etc. Please use this information accordingly.

NPI Number1881047637
Organization NameRutherford Crossing Dialysis
Doing Business AsTotal Renal Care, Inc.
Address141 Market St Winchester, Virginia, 22603
Phone Number(540) 665-5169

News Archive

Congress returns to face health program costs, budget issues

News outlets report that lawmakers are returning to work after a two-week recess, during which they faced emotional challenges from constituents regarding the deficit and the nation's entitlement programs.

Labopharm's public offering underwriters exercise over-allotment option to purchase additional 1.7M units

Labopharm Inc. today announced that the underwriters for the recently announced public offering of newly issued units have exercised in full their over-allotment option to purchase an additional 1,764,706 units. The 1,764,706 additional units are being sold at the public offering price of US$1.70 per unit and will bring the total number of units issued under the public offering to 13,529,412 units.

ONGLYZA-metformin combination: FDA accepts NDA for review

Bristol-Myers Squibb Company and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for an investigational fixed dose combination of ONGLYZA™ (saxagliptin), a dipeptidyl peptidase-4 (DPP4) inhibitor, and metformin HCl extended-release tablets as a once-daily treatment for type 2 diabetes mellitus in adults.

Smell produced by young bed bugs repels other bed bugs

Bed bugs are an increasingly common pest that necessitates extensive decontamination of homes. However, researchers from Lund and Sundsvall in Sweden have now discovered that young bed bugs produce a smell that repels other bed bugs. It is hoped that these findings could contribute to more effective control of the blood-sucking insects.

Countries most susceptible to toxic pollution are also at highest risk from the impacts of global climate change

Mapping the global distribution of toxic pollution alongside the effects of climate change shows the same countries are most vulnerable to both.

Read more Medical News

› Verified 7 days ago


Patient Distribution

Anemia Management

Dialysis patients with Hemoglobin data10

News Archive

Congress returns to face health program costs, budget issues

News outlets report that lawmakers are returning to work after a two-week recess, during which they faced emotional challenges from constituents regarding the deficit and the nation's entitlement programs.

Labopharm's public offering underwriters exercise over-allotment option to purchase additional 1.7M units

Labopharm Inc. today announced that the underwriters for the recently announced public offering of newly issued units have exercised in full their over-allotment option to purchase an additional 1,764,706 units. The 1,764,706 additional units are being sold at the public offering price of US$1.70 per unit and will bring the total number of units issued under the public offering to 13,529,412 units.

ONGLYZA-metformin combination: FDA accepts NDA for review

Bristol-Myers Squibb Company and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for an investigational fixed dose combination of ONGLYZA™ (saxagliptin), a dipeptidyl peptidase-4 (DPP4) inhibitor, and metformin HCl extended-release tablets as a once-daily treatment for type 2 diabetes mellitus in adults.

Smell produced by young bed bugs repels other bed bugs

Bed bugs are an increasingly common pest that necessitates extensive decontamination of homes. However, researchers from Lund and Sundsvall in Sweden have now discovered that young bed bugs produce a smell that repels other bed bugs. It is hoped that these findings could contribute to more effective control of the blood-sucking insects.

Countries most susceptible to toxic pollution are also at highest risk from the impacts of global climate change

Mapping the global distribution of toxic pollution alongside the effects of climate change shows the same countries are most vulnerable to both.

Read more Medical News

› Verified 7 days ago

Dialysis Adequacy

Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.

  • Hemodialysis
    Adult patients getting regular hemodialysis at the center22
    Adult patient months included in Kt/V greater than or equal to 1.2104
    Percentage of adult patients getting regular hemodialysis at the center94
    Percentage of pediatric patients getting regular hemodialysis at the center

    News Archive

    Congress returns to face health program costs, budget issues

    News outlets report that lawmakers are returning to work after a two-week recess, during which they faced emotional challenges from constituents regarding the deficit and the nation's entitlement programs.

    Labopharm's public offering underwriters exercise over-allotment option to purchase additional 1.7M units

    Labopharm Inc. today announced that the underwriters for the recently announced public offering of newly issued units have exercised in full their over-allotment option to purchase an additional 1,764,706 units. The 1,764,706 additional units are being sold at the public offering price of US$1.70 per unit and will bring the total number of units issued under the public offering to 13,529,412 units.

    ONGLYZA-metformin combination: FDA accepts NDA for review

    Bristol-Myers Squibb Company and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for an investigational fixed dose combination of ONGLYZA™ (saxagliptin), a dipeptidyl peptidase-4 (DPP4) inhibitor, and metformin HCl extended-release tablets as a once-daily treatment for type 2 diabetes mellitus in adults.

    Smell produced by young bed bugs repels other bed bugs

    Bed bugs are an increasingly common pest that necessitates extensive decontamination of homes. However, researchers from Lund and Sundsvall in Sweden have now discovered that young bed bugs produce a smell that repels other bed bugs. It is hoped that these findings could contribute to more effective control of the blood-sucking insects.

    Countries most susceptible to toxic pollution are also at highest risk from the impacts of global climate change

    Mapping the global distribution of toxic pollution alongside the effects of climate change shows the same countries are most vulnerable to both.

    Read more Medical News

    › Verified 7 days ago

Mineral and Bone Disorder

An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Rutherford Crossing Dialysis with elevated calcium levels.

Patients with hypercalcemia23
Hypercalcemia patient months108
Patients with Serumphosphor28
Patients with Serumphosphor less than 3.5 mg/dL9
Patients with Serumphosphor from 3.5 to 4.5 mg/dL27
Patients with Serumphosphor from 4.6 to 5.5 mg/dL41
Patients with Serumphosphor from 5.6 to 7 mg/dL13
Patients with Serumphosphor greater than 7 mg/dL10

News Archive

Congress returns to face health program costs, budget issues

News outlets report that lawmakers are returning to work after a two-week recess, during which they faced emotional challenges from constituents regarding the deficit and the nation's entitlement programs.

Labopharm's public offering underwriters exercise over-allotment option to purchase additional 1.7M units

Labopharm Inc. today announced that the underwriters for the recently announced public offering of newly issued units have exercised in full their over-allotment option to purchase an additional 1,764,706 units. The 1,764,706 additional units are being sold at the public offering price of US$1.70 per unit and will bring the total number of units issued under the public offering to 13,529,412 units.

ONGLYZA-metformin combination: FDA accepts NDA for review

Bristol-Myers Squibb Company and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for an investigational fixed dose combination of ONGLYZA™ (saxagliptin), a dipeptidyl peptidase-4 (DPP4) inhibitor, and metformin HCl extended-release tablets as a once-daily treatment for type 2 diabetes mellitus in adults.

Smell produced by young bed bugs repels other bed bugs

Bed bugs are an increasingly common pest that necessitates extensive decontamination of homes. However, researchers from Lund and Sundsvall in Sweden have now discovered that young bed bugs produce a smell that repels other bed bugs. It is hoped that these findings could contribute to more effective control of the blood-sucking insects.

Countries most susceptible to toxic pollution are also at highest risk from the impacts of global climate change

Mapping the global distribution of toxic pollution alongside the effects of climate change shows the same countries are most vulnerable to both.

Read more Medical News

› Verified 7 days ago

Vascular Access

The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.

Patients included in arterial venous fistula and catheter summaries 27
Patient months included in arterial venous fistula and catheter summaries 118
Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment81
Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer7

News Archive

Congress returns to face health program costs, budget issues

News outlets report that lawmakers are returning to work after a two-week recess, during which they faced emotional challenges from constituents regarding the deficit and the nation's entitlement programs.

Labopharm's public offering underwriters exercise over-allotment option to purchase additional 1.7M units

Labopharm Inc. today announced that the underwriters for the recently announced public offering of newly issued units have exercised in full their over-allotment option to purchase an additional 1,764,706 units. The 1,764,706 additional units are being sold at the public offering price of US$1.70 per unit and will bring the total number of units issued under the public offering to 13,529,412 units.

ONGLYZA-metformin combination: FDA accepts NDA for review

Bristol-Myers Squibb Company and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for an investigational fixed dose combination of ONGLYZA™ (saxagliptin), a dipeptidyl peptidase-4 (DPP4) inhibitor, and metformin HCl extended-release tablets as a once-daily treatment for type 2 diabetes mellitus in adults.

Smell produced by young bed bugs repels other bed bugs

Bed bugs are an increasingly common pest that necessitates extensive decontamination of homes. However, researchers from Lund and Sundsvall in Sweden have now discovered that young bed bugs produce a smell that repels other bed bugs. It is hoped that these findings could contribute to more effective control of the blood-sucking insects.

Countries most susceptible to toxic pollution are also at highest risk from the impacts of global climate change

Mapping the global distribution of toxic pollution alongside the effects of climate change shows the same countries are most vulnerable to both.

Read more Medical News

› Verified 7 days ago